#Icad inc full
ICAD lost -$0.35 per share the over the last 12 months.Ĭlick Here to get the full Stock Report for iCAD Inc stock. is a medical technology company, which engages in the provision cancer detection and therapy solutions. Over the past year the S&P 500 is up 31.25% while ICAD is up 11.08%. ICAD is up $0.07 from the previous closing price of $11.76 on volume of 93,210 shares.
The firm has also developed a technology namely Xoft Axxent electronic. Its products include powerlook tomo detection, powerlook density assessment, and vera look. ICAD Inc (ICAD) stock has gained 0.6% while the S&P 500 has fallen -0.24% as of 10:18 AM on Thursday, Aug 12. icad Inc provides cancer detection, radiation therapy and workflow solutions, primarily computer-aided detection and workflow solutions for breast, prostate and colorectal cancers. What's Happening With iCAD Inc Stock Today? Maggie Hassan, Democrat of New Hampshire, got a first-hand look Tuesday at new technology aimed at revolutionizing the breast-cancer screening and risk-assessment process during a visit to the Nashua headquarters of iCAD Inc., a medical technology development firm on Spit Brook Road.
This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. Thanks to fractional shares Stash allows you to purchase smaller pieces of investments, called fractional shares, rather than having to pay the full price for a whole share. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. is a provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer.
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.See Full ICAD Report Why are Analyst Ratings Important?Ī company's financial statements are a significant factor weighted by experts when analyzing a company's health. So, the shares are expected to perform in line with the market in the near future. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Īhead of this earnings release, the estimate revisions trend for Icad was mixed. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Įmpirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. While Icad has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?